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 Dexmedetomidine is a selective a2-adrenergic receptor agonist. Alpha receptors are 
mainly found in the central nervous system and within the smooth muscle that composes the 
majority of blood vessel walls (Giovannitti et al., 2015).  There are 3 subtypes of alpha receptors: 
a-2A, a-2B, and a-2C. The a-2A and a-2C are found in the central nervous system and the a-2B 
are the receptors found within vascular smooth muscle. More specifically, a2 receptors are 
located in the prejunctional area and inhibit neurotransmitter release and provide negative 
feedback; a1 receptors are postjunctional and mediate effects on target tissues (Giovannitti et al., 
2015).  Suppression of neural firing is achieved with all 3 receptors due to the fact that a-2A, a-
2B, and a-2C all inhibit adenylyl cyclase, thus inhibiting cyclic adenosine monophosphate, or 
cAMP (Giovannitti et al., 2015).  
The general role of cAMP is to act as a messenger in numerous transduction pathways 
that control cell processes such as transcription, protein expression, metabolism, regulation of 
neurotransmitter synthesis and regulation of membrane protein activity by converting 
extracellular signals to intracellular signals in stimuli received by receptors within the cell (Yan 
et al., 2016). The role of adenylyl cyclase is to catalyze the reaction of adenosine triphosphate 
into cAMP; therefore, when adenylyl cyclase is inhibited, so is cAMP (VIVO Pathophysiology). 
The inhibition of cAMP causes potassium to diffuse into the cell through calcium activated 
channels, ultimately preventing calcium from entering the axon terminal and leading to 
suppression of neural firing and inhibition of norepinephrine/ascending noradrenergic pathways 
(Giovannitti et al., 2015).  This change in ions and neurotransmitter pathways leads to sedation 
and hypnosis experienced by the patient A negative feedback loop is generated when alpha 
receptors are stimulated, further decreasing sympathetic response, which in turn decreases heart 
rate and blood pressure (Giovannitti et al., 2015). 
Dexmedetomidine has three main uses: prolonged sedation, procedural 
sedation/anesthesia, and decrease the incidence of emergence/postoperative delirium 
(Giovannitti et al., 2015). Postoperative delirium occurs following a surgical procedure and 
emergence delirium refers to delirium experienced immediately post-anesthesia. Both forms of 
delirium exhibit symptoms similar to dementia. The difference between the two is that once the 
cause of the postoperative delirium is found and treated, the symptoms will subside. Symptoms 
differ between patients, but disorientation, emotional dysregulation, sleep disturbances, and 
perceptual disturbances may occur (Oh & Park, 2019). The Diagnostic and Statistical Manual or 
Mental disorders, Fifth Edition, (DSM-5), criteria for delirium can be observed in Table 1 
(American Psychiatric Association, 2013). Currently, there is no sole factor that has been 
identified in the onset of delirium. The two leading hypotheses that attempt to explain the 
pathophysiology of delirium involve: cytokine interaction on the blood-brain barrier and 
neurochemical imbalances that affect transmission (Oh & Park, 2019). Upon completion of 
functional magnetic resonance imaging, it was found that individuals experiencing delirium 
demonstrated disruption of reciprocity functions within certain brain structures and a 







A:      A disturbance in attention (i.e., reduced ability to direct, focus, sustain, and shift 
attention) and awareness (reduced orientation to the environment) 
B:      The disturbance develops over a short period of time (usually hours to a few days), 
represents a change from baseline attention and awareness, and tends t fluctuate in severity 
during the course of a day 
C:     An additional disturbance in cognition (e.g., memory deficit, disorientation, language, 
visuospatial ability, or perception). 
D:     The disturbance in criteria A and C are not better explained by another preexisting, 
established, or evolving neurocognitive disorder and do not occur in the context of a severely 
reduced level of arousal, such as coma 
E:     There is evidence from the history, physical examination, or laboratory findings that the 
disturbance is a direct physiological consequence of another medical condition, substance 
intoxication or withdrawal (i.e., due to a drug of abuse or to a medication), or exposure to a 
toxin, or is due to multiple etiologies. 
(Table 1) 
Risk factors of postoperative delirium can be broken into 3 categories: preoperative, 
intraoperative, and postoperative. Preoperative factors include advanced age, comorbidities such 
as cardiovascular disease/anxiety disorders, preoperative fluid fasting/dehydration, 
hypo/hypernatremia, and drugs with anticholinergic effects (Oh & Park, 2019). Intraoperative 
risk factors include site of surgery being abdominal or cardiothoracic, and intraoperative 
bleeding; postoperative factors include pain (Oh & Park, 2019). Emergency surgery and 
postoperative complications raise risk for cognitive impairment and duration/severity of 
delirium. Studies have demonstrated that ICU patients who develop delirium while in the 
hospital have a higher chance of having a worse prognosis and a lower 6-month survival rate (Oh 
& Park, 2019). 
As aforementioned, dexmedetomidine is a selective a2-adrenergic receptor agonist and is 
primarily used for prolonged sedation, procedural sedation/anesthesia, and decrease the 
incidence of emergence/postoperative delirium (Giovannitti et al., 2015). It has been proposed 
that dexmedetomidine is associated with lower rates of postoperative delirium when used as 
procedural and postoperative sedation compared to midazolam or propofol (Hoy & Keating, 
2012). 
Purpose 
The purpose of this systematic review was to integrate research evidence from studies 
published from 2010 to 2020 on the relationship between administration of dexmedetomidine 
and severity/prevalence of postprocedural delirium in patients in the surgical intensive care unit. 
Methods 
 
This is a systematic review involving research that involves administration of 
dexmedetomidine in post-surgical intensive care unit patients and if it’s mechanism of action 
aids in preventing or decreasing instance and severity of delirium. This systematic review 
follows the guidelines outlined in the Preferred Reporting Items for Systemic Reviews and Meta-
Analyses statement (Liberati et al., 2009). 
Information Sources 
Clinical trial studies were recovered by searching the MEDLINE Complete and PubMed 
databases and utilizing MeSH terminology search. The electronic search was supplemented by a 
manual search from current issues of periodicals and follow-up of other cited materials. 
 
Search Strategy 
The MeSH terms utilized to search for applicable articles on PubMed included: 
“intensive care units” or “critical care” or “critical care nursing”, and “delirium”, 
“dexmedetomidine”, and “surgical procedures, operative”. On MEDLINE Complete, the search 
terms utilized were “ICU or intensive care unit or critical care” and “dexmedetomidine” and 
“delirium” and “surgical procedures, operative”. Search limiters applied to both databases 
included English language, and peer-reviewed journal articles from 2009-2020. 
Inclusion/Exclusion Criteria 
Eligibility of studies was determined by utilizing the PICO question established for this 
systematic review: (P) the study was conducted involving surgical intensive care unit patients, (I) 
a selective alpha-2 adrenoceptor agonist, specifically dexmedetomidine was administered to 
patients, (C) the study included data on the efficacy of dexmedetomidine in 
preventing/decreasing severity of delirium, and (O) prevalence of delirium compared to placebo 
was reported. Studies were excluded if they included an additional intervention in addition to 
dexmedetomidine, or if they included dexmedetomidine therapy for a reason other than delirium. 
Dexmedetomidine can benefit the patient in additional ways, such as providing hemodynamic 
stability to critically ill patients more effectively than other drugs (Chaitanya et al., 2014). 
Articles to be included were first screened through reading abstracts and going through the 
inclusion/exclusion criteria. Any discrepancies or uncertainties were consulted with a mentor 
experienced in writing academic literature. If multiple articles were published from one study, 
only the most complete and recent information was included. 
Data Extraction 
Relevant information was identified and extracted from the pertinent articles discovered. 
Authors, country of study, sample size, methods of data collection, reported results, year 
published, confounding variables (if any), limits, methods of data collection, and information 
regarding safety were analyzed throughout all of the relevant articles. The articles were further 
reviewed to ensure that the results were relevant to the proposed topic and from 2009 or later. 
The articles were read, and data was extracted, this process was completed twice as to avoid any 
missed information. The process results were compared, and any confusion/discrepancies were 
resolved. If any discrepancies were unable to be resolved, the article was not included in the 
review.  
Quality Assessment of Included Studies 
The modified Jadad score with 8 items (Table 2) was utilized to determine quality of the 
relevant studies. The Jadad scale includes randomization, blinding methods, description of 
withdrawals and dropouts, clear inclusion and exclusion criteria, adverse effects clearly 
described, and if the method of statistical evidence was described. The articles were scored twice 
to ensure appropriate scoring. Any articles with discrepancies in scores were scored again until a 
consistent score was achieved twice. Articles with a Jadad score of 4 or >4 were included in the 
systematic review, none needed to be excluded for this reason. 
 





Four articles were retrieved from MEDLINE Complete, and six articles were retrieved 
from PubMed.  Two articles were duplicates and removed. Seven articles went through full-text 
analysis. One article was removed because it involved research about dexmedetomidine and its 
effect on hemodynamics. Another article was removed because it explored delirium as a 
component in multisystem organ failure and a third article was removed because it was a pilot 
study and lacked results. After the full text analyses, 4 articles were included in the systematic 






















• The MeSH terms used in PubMed: “intensive care units” or 
“critical care” or “critical care nursing”, and “delirium”, 
“dexmedetomidine”, and “surgical procedures, operative” 
(n=5) 
• Limiters: last 10 years, Clinical Trial, and English 
• Search terms used in MEDLINE Complete: ICU or intensive 
care unit or critical care” and “dexmedetomidine” and 
“delirium” and “surgical procedures, operative” (n=5) 
• Search limiters: English and 2009-2020 
Initial search 
(n=9) 
Full-text review for further evaluation 
(n=7) 
Full-text articles included for this review 
(n=4)  
Articles excluded after duplicated articles found 
across 2 databases 
(n=2) 
Articles excluded after full-text review 
(n=3) 
• Dexmedetomidine in relationship to 
hemodynamics 
• Delirium related to multisystem organ 
failure 












 The first study had a sample size of 618 with 281 in the experimental group and 276 in 
the placebo group. The median age in the experimental group was 68 and the mean age in the 
placebo group was 69. The mean BMI were 24.6 and 24.3 respectively (Sun et al., 2019). 
Regarding chronic smoking, 20.6% and 19.9% are chronic smokers, respectively. Hypertension 
was found in 35.2% and 38.4%. Coronary artery disease 8.5% and 8.0%, diabetes 14.6% and 
15.6%, previous stroke 13.5% and 12% respectfully (Sun et al., 2019). All of the variables 
explored are < P=0.05, except for one. The CCI, median (IQR), in years was found to be 
statistically significant at 2.0 (0.0-2.0) and 1.0 (0.0-2.0) (P=0.010) (Sun et al., 2019). The study 
also explored surgical variables between the two groups and the significant difference included 
cancer, 50.9% in the dexmedetomidine group and 40.9% in the placebo group (P=0.019) (Sun et 
al., 2019). 
 The second article had a study group of 32 split into two groups, dexmedetomidine and 
midazolam. The mean age of 13.6 in the dexmedetomidine group and 14.8 in the midazolam 
group (Aydogan et al., 2013). The time under mechanical ventilation was found to be significant 
at 225 minutes in the midazolam group and 107 in the dexmedetomidine group (P=0.035) 
(Aydogan et al., 2013). Other variables found to be not significant included male/female 
distribution between the groups (9/7 in the midazolam group and 8/8 in dexmedetomidine 
group), height (156 cm and 153 cm respectively), weight (37kg and 28kg respectively), 
American Society of Anesthesiologists class II/III (10/6 and 11/5), and ICU length of stay (2 
days for both groups) (Aydogan et al., 2013). 
 The third study was larger and had a study group of 700, with 350 in a dexmedetomidine 
group and 350 in the placebo group. It was stated in the article that the groups were well matched 
for baseline/perioperative variables except in the dexmedetomidine group that percentage of 
patients with renal dysfunction preoperatively was lower in the dexmedetomidine group 
(creatinine > 177 µmol/L) (Su et al., 2016). The patients recruited were over the age of 65 and 
excluded aged less than 65 years, non-surgical patients, non-general anesthesia, neurosurgery, 
patients who required dialysis preoperatively, preoperative coma, and preoperative 
Parkinsonism. Regarding perioperative variables, 72% in the placebo group and 78.3% in the 
dexmedetomidine group had surgery for a malignant tumor, and both groups had intra-abdominal 
as the location of the surgery (67.1% in the placebo group and 68.6% in the dexmedetomidine 
group) (Su et al., 2016). The only significant difference was the number of patients who required 
intraoperative blood transfusion (19.1% in placebo group and 13.4% in dexmedetomidine group) 
(Su et al., 2016).  
The last study was a follow-up of the third study Ultimately after 3 years, 221 patients in 
the dexmedetomidine out of 350 participated (114 died, 13 lost at 3-year follow up, 2 refused 
assessment) and 213 in the placebo group participated (122 died, 10 lost at 3-year follow up, and 
5 refused assessment) (Zhang et al., 2019).  The mean age in the placebo group during follow-up 
was 74.5 and 74.2 in the dexmedetomidine group. Other variables that were not statistically 
different included but are not limited to: BMI 23.8 and 24.4 respectively, hypertension 64.3% 
and 62.9%, diabetes 24.4% and 28.5%, coronary artery disease 30% and 38%, stroke 22.5% and 
23.5%, alcoholism 8.9% and 7.2%, liver dysfunction 2.3% in both groups, renal dysfunction 
5.2% and 2.3% (Zhang et al., 2019).   
 The four articles included in this systematic review all explore effects of 
dexmedetomidine on cognitive functioning/decreasing delirium. The first study began with 618 
randomized patients after screening (Sun et al., 2019). 309 patients were placed into a group and 
ultimately 281 in the dexmedetomidine group received the allocated intervention and 276 
received the allocated intervention in the placebo group. Surgical cancellation, study drug 
infusion interrupted permanently, or unplanned ICU stay were reasons for participants not 
receiving the allocated intervention (Sun et al., 2019).  
Inclusion criteria included: aged 65 years of older, scheduled to undergo major elective 
noncardiac surgery under general anesthesia, American Society of Anesthesiologist physical 
status classification I to III, Mini Mental State Examination > or = to 20 points, and agreement to 
use patient-controlled intravenous analgesia pump. Exclusion criteria included emergency 
surgery, intracardiac or intracranial surgery, inability to communicate, sick sinus syndrome, 
sinus bradycardia, higher heart block in the absence of a pacemaker, serious liver dysfunction, 
serious kidney failure, schizophrenia, myasthenia gravis, Parkinson’s, allergy to opioids/a2-
adrenergic agonists, or prior recruitment in another clinical trial (Sun et al., 2019).  
Randomization was computer-generated to either the dexmedetomidine or placebo group 
and researchers remained blinded. Delirium was then assessed twice daily during the first five 
days following surgery with the RASS and CAM-ICU assessment tools (Sun et al., 2019). 
Postoperative delirium occurred in 12.7% (n=557) out of all patients and there was no significant 
difference between the placebo and experimental group (11.7% (33/218) in dexmedetomidine 
group and 13.8% (38/276) in the placebo group, p=0.47) (Sun et al., 2019). Although there was 
no statistical significance found between the groups in delirium prevention, the 
dexmedetomidine group had lower pain scores at four intervals after hour 1 post-surgery and 
required a lower percentage of pain rescue with flurbiprofen axetil (Sun et al., 2019). The 
dexmedetomidine group also was found to have higher sleep quality when assessed with the 
Richards Campbell Sleep Questionnaire (all p<0.0001). Additional outcomes included no 
significant differences in extubating time, 30-day mortality, and length of stay in the hospital 
(Sun et al., 2019). 5.3% (15/281) in the dexmedetomidine group experienced non-delirium 
related complications vs 5.1% (14/276) in the placebo group (p=0.89). Incidence on pneumonia 
was significantly lower in the dexmedetomidine group (0.4% (1/281) vs 2.5% (7/276 with 
p=0.036) (Sun et al., 2019).  
The second article explored pain, fentanyl consumption, and delirium following scoliosis 
surgery in adolescents (Aydogan et al., 2013). Inclusion criteria included admittance to ICU 
requiring mechanical ventilation with an endotracheal tube following scoliosis surgery. 
Exclusion criteria included allergy to dexmedetomidine or midazolam, delirium, developmental 
day, cognitive impairment, American Society of Anesthesiologists class > III, previous 
anesthetic adverse reactions, digoxin use, history of hypertension, chronic use of 
opioids/sedatives, or neuromuscular scoliosis/neurogenerative disease (Aydogan et al., 2013).  
As the previous study was, this study was also randomized and double-blinded. One 
group was to receive midazolam 0.1mg/kg/h IV and the other was to receive dexmedetomidine 
0.4 µg/kg/h IV and quality of sedation was assessed hourly through use of the RASS scale then 
the medication was titrated until desired RASS score was achieved (Aydogan et al., 2013). Pain 
relief was aimed to be kept between 0-4 on the Numeric Visual Analog Scale and if it was 
outside of the parameters then the medication would be titrated up or down. Delirium was 
assessed twice daily with the CAM-ICU scale in patients within the desired RASS score range (-
1 to +1) by a neurologist associated with the study (Aydogan et al., 2013). Haloperidol was given 
for treatment of agitation/delirium.  
Overall, the pain scores and cumulative fentanyl consumption were significantly higher 
in group MDZ than DEX. Pain was assessed at 1, 2, 4, 6 and 24 hours and at all hours the pain 
values in group DEX were lower and significant compared to MDZ group (p<0.05):  hour 1 
(P=0.012), hour 2 (P=0.003), hour 4 (P=0.001), hour 6 (P=0.003) and hour 24 (P=0.004). 
Fentanyl consumption was also assessed at the same hours following surgery and the MDZ 
group consistently had statistically significant higher values: hour 1 (P=0.006), hour 2(P=0.002), 
hour 4 (P=0.023), hour 6 (P=0.001) and hour 24 (P=0.002). Furthermore, delirium was 
significantly higher in the MDZ group (31.3% vs 12.5% and P<0.05) (Aydogan et al., 2013).  
Haloperidol was given to treat delirium in 1/16 (4%) of the patients in the DEX group as 
opposed to 4/16 (25%) of the patients in group MDZ. No significant differences occurred in 
mean arterial pressure. More patients in group DEX developed adverse events related due to 
treatment (6/16 [37.5%] vs 3/16 [18.7%]), most likely due to the significantly higher instance of 
bradycardia in the DEX group at all measured time intervals (P<0.05). 
The third article was a larger double-blind randomized control trial specifically exploring 
administration of dexmedetomidine and its effect on prevention of delirium in elderly patients 
following non-cardiac surgery. Dexmedetomidine was given at 0.1µg/kg/hr usually within one 
hour after ICU admission until 0800 the following day after surgery for non-intubated patients. 
Intubated and mechanically ventilated patients received the study drug infusion only after 
sedatives were titrated to achieve RASS of -2 or higher (Su et al., 2016). For pain, morphine or 
flurbiprofen axetil were given IV.  
Approaches to mitigating delirium were initiated as standard procedures for ICU patients 
(reorientation, cognitive stimulation, early ambulation, hearing/vision aids, sleep-promotion, and 
dehydration protocols) (Su et al., 2016). If a patient demonstrated delirium, first 
nonpharmacological strategies were implemented followed by haloperidol administration if 
needed (RASS +3 or greater). The primary endpoint of the study was calculating delirium 
incidence in the first week following surgery. The first assessment of delirium was performed 24 
hours after surgery then delirium was assessed twice daily (between 0800-1000 and 1800-2000) 
utilizing the CAM-ICU scale (Su et al., 2016).  
Like the other studies, RASS was utilized to gauge sedation level. In this study, if the 
RASS score was -3 to +4, delirium was assessed. Other factors assessed included extubation 
time, ICU/hospital length of stay, non-delirium postoperative complications, pain intensity, sleep 
quality (subjective), and 30-day mortality (Su et al., 2016). Pain was measured utilizing the 
Numeric Rating Scale (NRS: 0=no pain and 10=worst possible pain) at 3-, 6-, and 24-hours 
following surgery.  
Patients were followed up weekly following the first week for mortality rate (Su et al., 
2016). Before the final analysis, 143 patients were discharged before the first 7 days, 2 patients 
died (one in each group), 48 patients had to have the study drug modified due to adverse events. 
Delirium occurred in 79/350 (22.6%) of patients in the placebo group and in 32 (9.1%) out of the 
350 patients in the dexmedetomidine group (odds ratio 0.35, 95% CI 0.22-0.54; P<0.0001) (Su et 
al., 2016). Furthermore, daily prevalence of delirium was significantly higher in the placebo 
group on postoperative days 1 through 3 (day 1: 0.28, 0.16–0.50; P<0.0001, day 2: 0.43, 0.24–
0.77; P=0.005, day 3: 0.26, 0.13–0.53; P<0.0001) (Su et al., 2016). Regarding the secondary 
results, median time to extubation was longer in the placebo group (6.9h vs 4.6h) and percent of 
non-delirium complications was higher in the placebo group as well (21% vs 15% with 
P=0.039). There was no significance in length of hospital stay between the two groups or 30-day 
mortality, but post-hoc analysis demonstrated a higher percentage of patients discharged from 
the hospital within 7 days in the dexmedetomidine group (83 [24%] vs 60 [17%], P=0.032) (Su 
et al., 2016). Pain scores were found to be significantly lower in the dexmedetomidine group at 
3-, 6-, and 24- hours following surgery (all P<0.0001, except for one P=0.001 at 24-hours). The 
subjective sleep scores were also significantly better in the dexmedetomidine group the first 3 
days following surgery (P<0.001).  
The fourth and final article included in this review explored long-term (up to 3 years) 
effects and also postoperative outcomes up to 30 days in the patients that completed 3-year 
assessments of the trial that explored administration of dexmedetomidine and its effect on 
prevention of delirium in elderly patients following non-cardiac surgery (Su et al., 2016). The 
follow up was conducted by an investigator who was not involved in the original study and was 
blinded to the group assignments. For individuals who survived 3 years following surgery, 
cognitive function, was assessed with the modified Telephone Interview for Cognitive Status 
(TCIS-m) and the World Health Organization Quality of Life brief version (WHOQOL-BREF) 
involving physical, psychological, social relationship and environment domain assessment 
(Zhang et al., 2019).  
As aforementioned, these patients had been randomly assigned to receive 
dexmedetomidine 0.1µg/kg/h or normal saline at the same infusion rate. Of the original 700 
patients, 23 (3.3%) had passed away at follow-up, including 10 (2.9%) in the placebo group and 
13 (3.7%) in dexmedetomidine group (P=0.698) (Zhang et al., 2019).  Of the 441 survivors at 3 
years, 7 refused assessment (5 in placebo group and 2 in dexmedetomidine group). The 
remaining 434 completed the assessments previously mentioned (Zhang et al., 2019).  
 Overall, the 3-year survival rate did not differ significantly (mean survival length 29.9 
months, 95% CI 28.8 – 31.0 vs 28.2, 95% CI 26.9 – 29.5; and the 3-year survival rate of 67.0%, 
95% CI 62.1–71.9 vs 64.4%, 95% CI 59.3 – 69.5) and [hazard ratio (HR) for death 0.87, 95% CI 
0.68– 1.13, P=0.303) (Zhang et al., 2019). At shorter intervals, survival rates at 6 months were 
found to be higher in dexmedetomidine group (rate difference 5.2, 95% CI 1.1 – 9.3, P=0.012), 1 
year (5.3, 95% CI 0.0 – 10.6, P= 0.049), and 2 years (6.7, 95% CI 0.3–13.1, P=0.040) (Zhang et 
al., 2019). TICS-m (mean difference 4.7, 95% CI 3.8 – 5.6, P < 0.0001) and WHO- QOL-BREF 
(including physical: 13.6, 95% CI 10.6 – 16.6, P < 0.0001; psychological: 15.2, 95% CI 12.5 – 
18.0, P < 0.0001; social relationship: 8.1, 95% CI 5.5 – 10.7, P < 0.0001; and environment: 13.3, 
95% CI 10.9 – 15.7, P < 0.0001) assessments were higher in the dexmedetomidine group than in 
the placebo group, suggesting better cognitive functioning (Zhang et al., 2019). Involving 
delirium, the major interest in this review, incidence of delirium within the first 7 postoperative 
days (in the patients who completed 3-year assessments) was 41 (19.2%) in the placebo group 
and 18 (8.1%) in the dexmedetomidine group (P=0.001) (Zhang et al., 2019). Duration of 
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 Overall, dexmedetomidine was found to reduce incidence of delirium in patients who had 
received surgery in 2 studies (Aydogan et al., 2013; Su et al., 2016). In the other study 
conducted, there was no statistical significance between delirium incidence between the placebo 
and experimental group; and the last study was a follow-up of another one of the studies 
explored in this review. The groups of individuals included in the studies were individuals 65 
years or older undergoing major elective noncardiac surgery, adolescents receiving scoliosis 
surgery, and individuals aged 65 years or older, who were admitted to intensive care units after 
non-cardiac surgery. Besides delirium, secondary outcomes were also assessed across these 
studies such as: long-term effects, pain management, sleep, cognitive functioning (short and 
long-term), quality of life, mortality, hospital stay, time to extubation, and non-delirium related 
complications. Dexmedetomidine was found to have mixed results on delirium 
prevalence/severity across the studies explored in this review, but the majority of studies 
concluded statistical significance between dexmedetomidine and reduction in delirium (Aydogan 
et al., 2013; Su et al., 2016).   
 Regarding secondary outcomes, significantly lower pain scores were reported in all three 
studies. The first study reported a lower percentage of pain rescue, the second study reported 
statically significant lower pain scores 1-, 2-, 4-, 6-, and 24-hours following surgery delirium, 
and the third study reported lower pain scores at 3-, 6-, and 24 hours (Aydogan et al., 2013; Su et 
al., 2016; Sun et al., 2019). Two of the studies explored a placebo group versus 
dexmedetomidine while one study explored midazolam instead of a placebo group compared to 
dexmedetomidine. In the study involving midazolam, the midazolam group required significantly 
higher fentanyl consumption in order to lower pain levels (Aydogan et al., 2013). Regarding 
sleep quality, statistically significant higher sleep quality was reported in the two studies that 
explored this outcome (Su et al., 2016; Sun et al., 2019). In the two studies that extubation time 
was explored, there was no statistical significance found between the placebo groups and 
dexmedetomidine groups. The 30-day mortality rates showed no significant differences between 
the groups in the same two studies. (Su et al., 2016; Sun et al., 2019). All of the studies explored 
effects of dexmedetomidine on non-delirium related complications with three different findings. 
Firstly, one study showed no significance between the dexmedetomidine and placebo groups for 
non-delirium related complications (Sun et al., 2019). The second study found that more patients 
in the dexmedetomidine group experienced non-delirium related complications than in the 
midazolam group, and this number was found to be significant. Lastly, the third study found that 
the dexmedetomidine group had a significantly lower incidence in non-delirium related 
complications (Su et al., 2016). The two studies that explored length of stay between placebo and 
dexmedetomidine groups found no statistical significance (Su et al., 2016; Sun et al., 2019). In 
one study, it was found that there was a higher percentage in the dexmedetomidine group that 
were discharged from the hospital within 7 days. 
 Regarding long-term effects, this study was a follow-up of the study conducted in 2016 
(Su et al., 2016).  The 3-year survival was found to have no significant difference between the 
two groups, but the 3-month and 6-month survival rates were found to be higher in the 
dexmedetomidine group. It was specifically noted in this study that 80.1% of the patients in this 
study underwent surgery for cancer, and although tumor stages among the participants in two 
groups were comparable, this could still impact the survival rates between the two groups. In 
non-cancer patients (19.9%), survival in the dexmedetomidine group was significantly higher 
(Zhang et al., 2019). Furthermore, the initial study had found that delirium occurred significantly 
more in the placebo group than in the dexmedetomidine group. The follow-up also included a 
further analysis of the initial data and although the dexmedetomidine group had significantly 
lower instances of delirium, the duration of delirium was not found to differ significantly 
between the dexmedetomidine and placebo groups (Zhang et al., 2019). Regarding the 
assessment portion utilizing the Telephone Interview for Cognitive Status (TCIS-m) and the 
World Health Organization Quality of Life brief version (WHOQOL-BREF), psychosocial, 
social relationship, physical, and environmental domains were found to be significantly better in 
the dexmedetomidine group, suggesting better long-term cognitive functioning after receiving 
dexmedetomidine (Zhang et al., 2019).   
 The overall results across the three studies and follow-up suggest that when given 
dexmedetomidine following surgery, a patient has a better chance of not acquiring delirium. The 
three studies also suggest that pain and sleep quality are also improved when given 
dexmedetomidine. The three studies explored three different groups of individuals: individuals 
65 years or older undergoing major elective noncardiac surgery, adolescents receiving scoliosis 
surgery, and individuals aged 65 years or older, who were admitted to intensive care units after 
non-cardiac surgery. Although the different groups allow for data to be collected among different 
populations, a limit of this review is that there needs to be multiple trials over multiple age 
groups in order to determine the efficacy of dexmedetomidine. Similarly, this topic has very 
limited high-quality research with randomized control trials. There is great room for an increase 
in research on this topic. Overall, the results show promising trends, but there is not enough data 
to concretely determine the effects of dexmedetomidine when given to postoperative patients.  
Although the results are limited, they are encouraging. Further research in this field could 
lead to new protocols for postoperative patients who have undergone major surgeries. Positive 
findings possible include reduced incidence in delirium, better long-term cognitive functioning, 
decreased time to extubation, decreased pain medication consumption, decreased overall pain, 
and better sleep quality. This review has explored three randomized control trials and one follow 
up of one of the randomized control trials. Recommendations in order to advance findings may 
include conducting randomized control trials in the United States/other countries where 
demographics are different, conducting trials among all age groups, and conducting high-quality 
long-term follow up studies of the trials like the one explored in this review. 
 
Conclusion 
 Currently, there is insufficient evidence regarding use of dexmedetomidine in 
prevention/decreasing severity of postoperative delirium in the surgical ICU setting. Although 
there is limited evidence, the evidence is still encouraging and has shown evidence in being 
effective in mitigating delirium. As aforementioned, across the 3 randomized trials and the 3-
year follow up article, there has been other positive findings found with dexmedetomidine use 
including better long-term cognitive functioning, decreased time to extubation, decreased pain 
medication consumption, decreased overall pain, and better sleep quality. Overall, there needs to 
be more research and deeper exploration into the use of dexmedetomidine in order to create a 
solid foundation of knowledge on the benefits and risks of utilizing this medication in patients 
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